Login to Your Account

FDA Turns Down Cellegy's Cellegesic For Anal Fissures

By Karen Pihl-Carey

Tuesday, December 28, 2004
Shares of Cellegy Pharmaceuticals Inc. sank nearly 45 percent Monday, following news late last week that the FDA issued a not approvable letter for the company's anal fissure product, Cellegesic. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription